Navigation Links
Encision Reports Profitable Fourth Quarter and Fiscal Year 2011 Results

BOULDER, Colo., June 1, 2011 /PRNewswire/ -- Encision Inc. (Pink Sheets: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported profitable financial results for its fourth fiscal quarter ended March 31, 2011.

The Company recorded net income of $35,000 or $0.01 per share for the fourth quarter of fiscal year 2011 on net sales of $2.921 million, representing an 8% decrease from net sales of $3.186 million for the fourth quarter of fiscal year 2010. The Company's net income compared favorably to the $94,000 net loss, or $(0.01) per share for the fourth quarter of fiscal year 2010.

Gross profit margin for the fourth quarter of fiscal year 2011 was 58.7% as compared to 59% for the fourth quarter of fiscal year 2010. In the fourth quarter of fiscal year 2010, the gross profit margin decreased 3% as a result of an inventory reserve increase of $96,000 relating to the removal of product from inventory. Therefore, on a comparable adjusted basis, the gross profit margin for the fourth quarter of fiscal year 2011 decreased from the fourth quarter of fiscal year 2010. Principally, this was a result of a planned manufacturing slowdown that resulted in higher product unit costs.

"We are disappointed in the reduced sales for the fiscal year. However, even with our reduced sales, we managed to have a small net income for our fiscal year 2011 due to the $269 thousand of net income that we recorded in the second half of the fiscal year," said Jack Serino, President and CEO of Encision Inc.

"In fiscal year 2012, we will release new products for broader market access, focus on regrowing our AEM® franchise through a social media campaign to increase the discussion about stray energy burns during laparoscopy and our unique solution, especially during single or reduced port surgery, and accelerate a medico-legal initiative with healthcare facilities' insurance stakeholders. In addition, prior years' efforts in vertical integration have given us three recognized core competencies – electrosurgery, instrument design, and manufacturing – which we expect will allow us to increase sales from our strategic partnership initiatives."

Net sales for the fiscal year ended March 31, 2011 totaled $11.617 million, representing a 9.5% decrease from net sales of $12.836 million for the fiscal year ended March 31, 2010. The Company recorded net income of $5,000 or $0.00 per share for the fiscal year ended March 31, 2011 compared to net income of $265,000 or $0.04 per share for the fiscal year ended March 31, 2010. Gross profit margin for the fiscal year ended March 31, 2011 was 62.1% as compared to 61.3% for the fiscal year ended March 31, 2010. The higher gross profit margin in the fiscal year ended March 31, 2011 as compared to the gross profit margin in the fiscal year ended March 31, 2010 was due to a decrease of 0.8% of gross profit in the fiscal year ended March 31, 2010 as a result of an inventory reserve increase, as explained above. Therefore, on an adjusted basis, the gross profit margins were comparable for both fiscal years.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2010 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:  Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.comEncision Inc.Condensed Balance Sheets(Amounts in thousands)(Audited)March 31, 2011March 31, 2010ASSETSCash and cash equivalents$
4Accounts receivable, net1,1601,286Inventories, net2,6042,477Prepaid expenses7443 Total current assets3,9583,920Equipment, net1,1691,149Patents, net260266Other assets2424 Total assets$ 5,411$ 5,359LIABILITIES AND SHAREHOLDERS' EQUITYAccounts payable$
84Accrued compensation261405Other accrued liabilities287277Line of credit435-- Total current liabilities1,6571,366Line of credit--350Common stock and additional paid-in capital19,78319,677Accumulated (deficit)(16,029)(16,034) Total shareholders' equity3,7543,643 Total liabilities and shareholders' equity$ 5,411$  5,359Encision Inc.Condensed Statements of Operations(Amounts in thousands, except per share information)(Audited)Three Months EndedFiscal year EndedMarch 31, 2011March 31, 2010March 31, 2011March 31, 2010Net sales$ 2,921$ 3,186$ 11,617

$ 12,836Cost of sales1,2071,3054,404

4,969Gross profit1,7141,8817,213

7,867Operating expenses: Sales and marketing1,0171,1784,242

4,758 General and administrative3244051,457

1,464 Research and development3283921,464

1,339Total operating expenses1,6691,9757,163

7,561Operating income (loss)45(94)50

306Interest and other income (expense), net(10)0(45)

(41)Income before provision for income taxes35(94)5

265Provision for income taxes––––––

––Net income (loss)$
35$   (94)$

265Net income per share—basic and diluted$   0.01$ (0.01)$   0.00

.04Basic weighted average number of shares6,4556,4556,455

6,455Diluted weighted average number of shares6,4646,4556,465


SOURCE Encision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Encision Reports Profitable Third Fiscal Quarter Results
2. Encision and HealthTrust Purchasing Group Sign Purchasing Agreement
3. Encisions Technology Recognized as A Means to Eliminate Surgery Burns
4. Encisions Active Electrode Monitoring Technology Recommended at Minimally Invasive Gynecology Congress
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
(Date:11/30/2015)... 2015 Mexico Healthcare and Life Sciences Report ... 2015 . --> Pharmaboardroom releases its new 98-page ... Latin America , a country of over 122 million people. ... over 122 million people. --> It offers companies, investors, ... sciences insights into the second largest pharma and healthcare market in ...
(Date:11/29/2015)... Nov. 29, 2015   Royal Philips  (NYSE: PHG, ... solutions at the 2015 Radiological Society of North America ... McCormick Place in Chicago . Visitors ... the company,s broad portfolio of integrated Diagnostic Imaging, Clinical ... increase clinical performance, improve workflow and create a superior ...
(Date:11/27/2015)... Pays-Bas, November 27, 2015 ... traitement photodynamique au Bremachlorin contre le cancer avancé. ... consistant à combiner l,immunothérapie au traitement photodynamique au ... --> Une nouvelle approche consistant à ... le cancer avancé.    Clinical ...
Breaking Medicine Technology:
(Date:11/30/2015)... Grove, IL (PRWEB) , ... November 30, 2015 , ... ... for an emerging pharmaceutical company. Because it is so important to this key industry ... “Success Factors in your IND Filing” on December 4th at 11am EST. , Federal ...
(Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... November 30, 2015 , ... Bayco Products, Inc today announced the introduction of three ... in a choice of three different colors; red ( NSP-1632 ), yellow ( NSP-1634 ) ... to 18 hours in constant-on mode, or 27 hours in blinking strobe mode using a ...
(Date:11/29/2015)... ... 30, 2015 , ... The Cyber Monday deal is a deep 40% or more discount on ... get gifts for the skin care lover in your circle. Each Christmas, Sublime Beauty ... year, the 3 serums are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking stuffers like ...
Breaking Medicine News(10 mins):